Consistent t(1;10) with rearrangements of TGFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor
- 29 June 2011
- journal article
- research article
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 50 (10), 757-764
- https://doi.org/10.1002/gcc.20897
Abstract
Despite their shared predilection for superficial soft tissue of distal extremities and frequent local recurrences, myxoinflammatory fibroblastic sarcoma (MIFS) and hemosiderotic fibrolipomatous tumor (HFLT) have distinct morphologic appearances. Recent studies have identified an identical t(1;10)(p22;q24) in five cases of MIFS and two of HFLT, as well as common amplifications on 3p11‐12. To investigate further their potential relationship and to determine the incidence of t(1;10) in a larger cohort, we subjected seven MIFS, 14 HFLT, and three cases with mixed morphology, to molecular and cytogenetic analysis. Fluorescence in situ hybridization (FISH) analysis for rearrangements of TGFBR3 on 1p22 and of MGEA5 on 10q24 was performed in all cases, whereas the status of VGLL3 gene amplification on 3p12.1 was investigated in 12 cases. Conventional karyotyping was performed in one HFLT and two cases with mixed MIFS/HFLT histology. Overall 83% of cases showed rearrangements in both TGFBR3 and MGEA5. All three cases with mixed features of MIFS and HFLT were positive. Cytogenetic analysis performed in three cases confirmed an unbalanced der(10)t(1;10)(p22;q24). VGLL3 gene amplification was noted in 10/12 cases of both histologies. The high incidence of t(1;10) in MIFS and HFLT reinforces a shared pathogenetic relationship. Furthermore, the co‐existence of both components either synchronously or metachronously in a primary or subsequent recurrence, suggest either different morphologic variants or different levels of tumor progression of a single biologic entity. FISH analysis for TGFBR3 and MGEA5 rearrangements can be applied as a reliable diagnostic molecular test when confronted with limited material or a challenging diagnosis.Keywords
This publication has 22 references indexed in Scilit:
- Hybrid Myxoinflammatory Fibroblastic Sarcoma/Hemosiderotic Fibrolipomatous Tumor: Report of a Case Providing Further Evidence for a Pathogenetic LinkThe American Journal of Surgical Pathology, 2010
- YAP1 and VGLL3, encoding two cofactors of TEAD transcription factors, are amplified and overexpressed in a subset of soft tissue sarcomasGenes, Chromosomes and Cancer, 2010
- EWSR1‐POU5F1 fusion in soft tissue myoepithelial tumors. A molecular analysis of sixty‐six cases, including soft tissue, bone, and visceral lesions, showing common involvement of the EWSR1 geneGenes, Chromosomes and Cancer, 2010
- Early Pleomorphic Hyalinizing Angiectatic Tumor: Precursor or Distinct Lesion?Orthopedics, 2010
- Two genetic pathways, t(1;10) and amplification of 3p11–12, in myxoinflammatory fibroblastic sarcoma, haemosiderotic fibrolipomatous tumour, and morphologically similar lesionsThe Journal of Pathology, 2009
- Haemosiderotic fibrolipomatous tumour (so‐called haemosiderotic fibrohistiocytic lipomatous tumour): analysis of 13 new cases in support of a distinct entityHistopathology, 2006
- Functions and regulations of fibroblast growth factor signaling during embryonic developmentDevelopmental Biology, 2005
- Disruption of Fibroblast Growth Factor Signal Pathway Inhibits the Growth of Synovial Sarcomas: Potential Application of Signal Inhibitors to Molecular Target TherapyClinical Cancer Research, 2005
- Hemosiderotic Fibrohistiocytic Lipomatous Lesion: Ten Cases of a Previously Undescribed Fatty Lesion of the Foot/ankleLaboratory Investigation, 2000
- Acral Myxoinflammatory Fibroblastic SarcomaThe American Journal of Surgical Pathology, 1998